Damora Therapeutics (DMRA) Cash from Operations (2019 - 2026)
Damora Therapeutics (DMRA) reported Cash from Operations of 20600000.0 for Q1 2026, down 758.33% on a YoY basis from 3129113.92 in Q1 2025, and down 3688.85% quarter-over-quarter from 574000.0 in Q4 2025.
Damora Therapeutics (DMRA) Cash from Operations (2019 - 2026) Analysis & Trends
Damora Therapeutics has reported Cash from Operations for 8 years, with the latest figure at 20600000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 758.33% year-over-year to 20600000.0; the trailing twelve-month figure through Mar 2026 stood at 24926000.0 (down 65.07% YoY), and the FY2025 full-year result was 6726000.0, up 63.84% from the prior year.
- Cash from Operations for Q1 2026 stood at 20600000.0, down from 574000.0 in the prior quarter.
- The five-year high for Cash from Operations was 574000.0 in Q4 2025, with the low at 20600000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 7397529.41 across 5 years, with a median of 6797000.0 in 2022.
- Annual changes were most pronounced in 2025 — Cash from Operations surged 111.68% — and 2026, when it tumbled 758.33%.
- Damora Therapeutics' Cash from Operations stood at 11448000.0 in 2022, then dropped by 0.13% to 11463000.0 in 2023, then jumped by 57.14% to 4913000.0 in 2024, then surged by 111.68% to 574000.0 in 2025, then slumped by 3688.85% to 20600000.0 in 2026.
- The last three Cash from Operations figures came in at 20600000.0 (Q1 2026), 574000.0 (Q4 2025), and 2600000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - | -20.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.60 Mn |
| Mar 31, 2026 | -20.60 Mn |
| Dec 31, 2025 | 574,000.00 |
| Dec 31, 2025 | 574,000.00 |
| Sep 30, 2025 | -2.60 Mn |
| Sep 30, 2025 | -2.60 Mn |
| Jun 30, 2025 | -2.30 Mn |
| Jun 30, 2025 | -2.30 Mn |
| Mar 31, 2025 | -2.40 Mn |
| Mar 31, 2025 | -2.40 Mn |
| Dec 31, 2024 | -4.91 Mn |
| Dec 31, 2024 | -4.91 Mn |
| Sep 30, 2024 | -3.69 Mn |
| Sep 30, 2024 | -3.69 Mn |
| Jun 30, 2024 | -4.10 Mn |
| Jun 30, 2024 | -4.10 Mn |
| Mar 31, 2024 | -5.90 Mn |
| Mar 31, 2024 | -5.90 Mn |
| Dec 31, 2023 | -11.46 Mn |
| Dec 31, 2023 | -11.46 Mn |